Where the corridors of power intersect with groundbreaking research, JLABS @ Washington DC is a haven of innovation. As part of the global Johnson & Johnson Innovation network, JLABS is more than just a state-of-the-art facility; it’s a thriving ecosystem designed to accelerate life sciences innovation. Since its inception, JLABS has played a pivotal role in fostering the growth of early-stage companies and strengthening the region’s burgeoning biotech sector.
A Nexus of Opportunity
JLABS @ Washington, DC opened its doors in 2021, strategically located at the Children’s National Research & Innovation Campus in Northwest D.C., on the historic site of the former Walter Reed Army Medical Center. This 32,000-square-foot facility provides startups with access to capital-efficient lab space, cutting-edge equipment, and a robust support system. It is a place where entrepreneurs, innovators, and startups in the healthcare spectrum—including pharmaceuticals, medical devices, and health tech—can transform their ideas into realities.
“The proximity to federal research institutions, universities, and academic research centers makes JLABS @ Washington, DC an ideal hub for life sciences innovation,” says Rachel Rath, Interim Head of JLABS @ Washington, DC. “We are positioned at the crossroads of scientific discovery and policy, allowing our resident companies to capitalize on the wealth of resources available in the nation’s capital.”
The Power of Partnerships
One of the critical strengths of JLABS @ Washington, DC lies in its collaborative approach. Through strategic partnerships with regional stakeholders like Children’s National Hospital, the Biomedical Advanced Research and Development Authority (BARDA), and other institutions, JLABS has created a network that supports early-stage companies from inception through commercialization.
These collaborations are exceptionally vital for initiatives like BLUE KNIGHT™, a joint effort between Johnson & Johnson Innovation and BARDA. Blue Knight aims to stimulate early-stage companies that are strategically aligned to mutual areas of interest between BARDA and the Johnson & Johnson Family of Companies, with a particular interest in multi-use technologies with commercial and preparedness applications. JLABS @ Washington DC serves as the central hub for this initiative, offering residency opportunities and expert programming to stimulate innovation in this critical field.
“We’re proud to support Blue Knight companies through access to the JLABS ecosystem, including modular lab units, office space, shared core laboratory equipment, and business facilities,” notes Rath, who also serves as the BARDA Alliance Director for Johnson & Johnson Innovation. “Our unique offerings, such as fee assistance for access to JLABS and limited-competition non-dilutive funding opportunities, are critical in helping companies advance their innovations.”
A Platform for Success
JLABS @ Washington, DC operates under a no-strings-attached model, allowing companies the freedom to partner and collaborate without restrictions. This approach has proven successful, with the site supporting over 55 early-stage companies in just three years. Collectively, these companies have raised over $600 million in financing and strategic relationships, fueling their growth and expanding the region’s life sciences ecosystem.
Recent success stories include Nanochon, which raised $4 million in a Series Seed Prime round, and Acclinate, which secured $7 million in a Series A round. Additionally, companies like Astek Diagnostics have forged strategic partnerships with organizations such as MedStar Health, further validating the impact of JLABS @ Washington, DC.
Driving Scientific Thought Leadership
Beyond infrastructure and funding, JLABS @ Washington, DC recognizes the importance of driving scientific discussions and investor networking. The site regularly hosts panel discussions and symposia, such as the Pediatric Medical Devices symposium in partnership with Children’s National and CobiCure, and a thought-provoking session on “Harnessing the Potential of Antibody Drug Conjugates in Oncology.” These events provide a platform for innovators to engage with experts and investors, fostering a culture of continuous learning and collaboration.
JLABS @ Washington, DC hosts an annual Investor & Partnering Day. The 2024 event connected early-stage companies with investor groups, resulting in over 300 one-on-one meetings. These events are instrumental in helping companies secure the capital needed to advance their research and development efforts.
Expanding Access to Innovation
Recognizing the need for broader access to specialized resources, JLABS @ Washington, DC recently launched a program allowing external innovators to access certain research equipment and instruments at the facility. This initiative aims to support early-stage biotech companies that may not have the resources to invest in high-end equipment.
A Bright Future Ahead
JLABS @ Washington, DC is more than just a place for startups to set up shop; it’s a launchpad for innovation. By providing access to top-tier facilities, expert mentorship, and a global network of partners, JLABS is empowering the next generation of life sciences leaders to tackle some of the world’s most pressing health challenges.
As JLABS @ Washington, DC continues to grow, it remains committed to its mission of accelerating innovation and transforming healthcare. With a focus on collaboration, cutting-edge science, and strategic partnerships, the future is bright for the innovators who call JLABS home.
“Unlocking the collective power of the global community is key to addressing 21st-century health threats,” says Rath. “JLABS @ Washington, DC is at the forefront of this effort, and we are excited to see what the future holds.”
JLABS @ Washington, DC is not just a part of the capital’s innovation landscape—it’s helping to shape it. Through its unwavering commitment to supporting startups and driving life sciences forward, JLABS is setting a new standard for what’s possible in the world of healthcare innovation.
